Cancer therapy requires a careful balance maximizing therapeutic efficacy while minimizing patient toxicity. The ideal cancer treatment would direct therapy selectively to tumor cells while sparing normal cells and tissues. With intellectual property fully and exclusively licensed from MD Anderson Cancer Center and the University of New Mexico, AAVP Biosystems (“AAVP”) has developed a targeted gene delivery vector that accomplishes this goal. The company intends to complete pre-clinical and IND-enabling requirements in 2017, and transition quickly into a first-in-human clinical trial.